Effect of long-term treatment with rosiglitazone on arterial elasticity and metabolic parameters in patients with Type 2 diabetes mellitus: a 2-year follow-up study
- 24 August 2007
- journal article
- Published by Wiley in Diabetic Medicine
- Vol. 24 (11), 1254-1260
- https://doi.org/10.1111/j.1464-5491.2007.02231.x
Abstract
Thiazolidinediones may influence the atherogenic process by improving cardiovascular risk factors. The present study was designed to determine the long-term effect of rosiglitazone on arterial compliance and metabolic parameters in patients with Type 2 diabetes. In an open-label, prospective study, 65 diabetic patients received rosiglitazone orally (4-8 mg/day) for 6 months. After 6 months, the patients continued an open follow-up study and were divided into two groups: group 1 included patients continuing rosiglitazone for 2 years, group 2 included patients discontinuing rosiglitazone and receiving other oral glucose-lowering agents. Lipid profile, glycated haemoglobin (HbA1c), insulin, C-peptide, fibrinogen, high-sensitivity-CRP and homeostasis model assessment-insulin resistance were measured. Arterial elasticity was assessed using pulse wave contour analysis. In patients treated with rosiglitazone for 2 years: the large artery elasticity index (LAEI) increased from 10.0 +/- 4.6 to 13.9 +/- 4.7 ml/mmHg x 100 after 2 years (P = 0.003). The small artery elasticity (SAEI) index increased significantly from 3.2 +/- 1.2 to 5.1 +/- 1.9 (P < 0.0001). In patients who discontinued rosiglitazone: LAEI did not change after 6 months, but decreased from 12.1 +/- 5.4 to 8.9 +/- 3.9 ml/mmHg x 10 (P < 0.0001) at the end of 2 years. SAEI increased during the first 6 months of treatment, from 3.9 +/- 1.8 to 5.1 +/- 1.5 ml/mmHg x 100 (P < 0.0001) and decreased after discontinuation of rosiglitazone (P = 0.042). Prolonged treatment with rosiglitazone improved arterial elasticity. However, significant deterioration in LAEI and SAEI was observed in patients who discontinued rosiglitazone. The beneficial vascular effect of rosiglitazone on arterial elasticity was independent of glycaemic control.Keywords
This publication has 22 references indexed in Scilit:
- Pioglitazone Decreases Carotid Intima-Media Thickness Independently of Glycemic Control in Patients With Type 2 Diabetes MellitusCirculation, 2005
- Mechanisms, Pathophysiology, and Therapy of Arterial StiffnessArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Effect of Rosiglitazone on Common Carotid Intima-Media Thickness Progression in Coronary Artery Disease Patients Without Diabetes MellitusArteriosclerosis, Thrombosis, and Vascular Biology, 2004
- Aortic Pulse-Wave Velocity and Its Relationship to Mortality in Diabetes and Glucose IntoleranceCell Metabolism, 2002
- Structure, Endothelial Function, Cell Growth, and Inflammation in Blood Vessels of Angiotensin II–Infused RatsCell Metabolism, 2002
- Characterization of an inhibitory effect of pioglitazone on balloon-injured vascular smooth muscle cell growthMetabolism, 2001
- Potent Inhibitory Effect of Troglitazone on Carotid Arterial Wall Thickness in Type 2 DiabetesJournal of Clinical Endocrinology & Metabolism, 1998
- Noninvasive Pulse Wave Analysis for the Early Detection of Vascular DiseaseHypertension, 1995
- Non–Insulin-Dependent Diabetes Mellitus and Fasting Glucose and Insulin Concentrations Are Associated With Arterial Stiffness IndexesCirculation, 1995
- Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in manDiabetologia, 1985